, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Sanofi, we had the pleasure of speaking with Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about key data from the phase 3 IRAKLIA study (NCT05405166), which investigated the use of isatuximab-irfc (Sarclisa) plus pomalidomide and dexamethasone administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma. Dr Leleu is a professor, head of the Myeloma Clinic, and head of the Department of Hematology at Hôpital La Mileterie in Poitiers, France. Dr Faiman is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio.

In our exclusive interview, Drs Leleu and Faiman discussed the unique methods and design of IRAKLIA, key efficacy and safety findings from this trial, and the benefits of using on-body delivery systems to deliver effective therapies to patients in more convenient and patient-centered ways.

That’s all we have for today! Thank you for listening t

, supported by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Podcasts

Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, discuss key data from the phase 3 IRAKLIA study. 

Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, Phase 3 IRAKLIA study

Videos

Xavier Leleu, MD, PhD, presents primary results from the Phase 3 IRAKLIA study demonstrating noninferior efficacy and a favorable safety profile of subcutaneous versus intravenous isatuximab, both combined with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, Phase 3 IRAKLIA study

Xavier Leleu, MD, PhD, professor, head, Department of Hematology, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

In a retrospective cohort study on the survival outcomes of patients with multiple myeloma in France, which was presented at the 2022 EHA Congress, 14,309 patients who were diagnosed with multiple myeloma from January 2013 to December 2019 were evaluated using the French National Healthcare Database. This study found that patients with multiple myeloma experienceddeteriorating survival outcomes with increased time from diagnosis and with each additional line of treatment.

Although frontline myeloma treatment is improving, with several new options being introduced over the past decades, therapies in advanced lines are lacking, Leleu says. Once a myeloma drug proves effective and tolerable in later lines, it is moved to the frontline setting, where it can perform even better, Leleu explains. However, no myeloma drugs stay in the advanced setting, and none have been developed specifically for this setting, meaning progress in later lines is often short-lived, Leleu notes.

Patients with multiple myeloma who progress to third or fourth lines of therapy often do so within 5 to 10 years of diagnosis, preventing myeloma from becoming a chronic or curable disease for the majority of patients, Leleu says. This retrospective study emphasizes the need for more effective treatments designed for later-line use, Leleu concludes.

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Xavier Leleu, MD, PhD

Articles

Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, Phase 3 IRAKLIA study

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma